Stay updated on P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page.

Latest updates to the P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedRevision: v3.4.2 was added and v3.4.1 was removed. This appears to be a maintenance/version update that does not modify study details or page content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check19 days agoChange DetectedRevision update: v3.4.1 added, replacing v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check27 days agoChange DetectedThe page adds a 'Show glossary' option and updates metadata labels: 'Last Update Submitted that Met QC Criteria', 'No FEAR Act Data', and 'Revision: v3.4.0'. The previous labels were 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4'.SummaryDifference0.2%

- Check41 days agoChange DetectedThe page now displays Revision: v3.3.4, replacing Revision: v3.3.3. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check62 days agoChange DetectedLocations section added with California as a site and revision updated to v3.3.3; HHS Vulnerability Disclosure and California Locations labels were removed.SummaryDifference0.2%

- Check85 days agoChange DetectedThe only change is a revision update from v3.3.1 to v3.3.2 with no changes to study content visible. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page.